Early Phase 1 Alzheimer's Disease Trial, Recruiting NCT04740580 Sponsor: Baylor College of Medicine Condition: Alzheimer's Disease
Back to Alzheimers Disease

Early Phase 1 Alzheimer's Disease Trial, Recruiting

NCT04740580
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 55 and 85 years old
  • People who have had gradual, worsening memory loss for more than 1 year, with a memory and thinking test score (called the Montreal Cognitive Assessment) between 10 and 20
  • People whose brain scan (a PET scan) shows the presence of a substance called amyloid, which is linked to memory conditions
  • People who have a family member, friend, or carer who is available to take part in the study alongside them as a "study partner"

Who may not be able to join:

  • People who have been admitted to hospital in the past 3 months
  • People who currently use insulin medications
  • People who have a thyroid condition that is not being treated
  • People whose kidney function blood test (creatinine) result is above a certain level (confirm with trial site)
  • People whose blood count shows a low level of haemoglobin (confirm with trial site)
  • People with a known liver disease, or whose liver enzyme blood test results are above a certain threshold
  • People with a history of stroke, a brain tumour, active heart failure, or active cancer (note: certain minor skin cancers that can be fully removed may not be excluded — confirm with trial site)
  • People with untreated depression or other serious mental health conditions
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Rajagopal V Sekhar, M.D., Baylor College of Medicine

Phone: 7137983908

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
15 February 2022
Est. completion
30 April 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cognition; Brain glucose uptake; Brain inflammation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov